Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignanciesJordan Gauthier, Cameron J. Turtle, Evandro D. Bezerra et al.|Blood|2020Cited by 217
Aetiology and outcomes of secondary myelofibrosis occurring in the context of inherited platelet disorders: A single institutional study of four patientsAntoine N. Saliba, Mrinal M. Patnaik, Alejandro Ferrer et al.|British Journal of Haematology|2020Cited by 12
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemiaYannis K. Valtis, Jae H. Park, Evan C. Chen et al.|Blood Advances|2025Cited by 3
NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free SurvivalYannis K. Valtis, Shabaz Malik, David Nemirovsky et al.|Blood|2024Cited by 3
Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and AboveIbrahim N. Muhsen, Kristen M. O'Dwyer, Anjali S. Advani et al.|Blood|2024Cited by 3